HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.

AbstractOBJECTIVE:
To evaluate the efficacy of lurasidone for schizophrenia using an established five-factor model of the Positive and Negative Syndrome Scale (PANSS).
METHODS:
Patient-level data were pooled from five randomized, double-blind, placebo-controlled, 6-week studies of lurasidone (fixed doses, 40-160mg/d) for patients with an acute exacerbation of schizophrenia. Changes in five established PANSS factors were assessed using mixed-model repeated measures analysis.
RESULTS:
Compared with placebo (n=496), lurasidone (n=1029, dose groups pooled) significantly improved the PANSS total score at Week 6 (-22.6 vs. -12.8; P<0.001; effect size, 0.45), as well as all factor scores (P<0.001 for each): positive symptoms (-8.4 vs. -6.0; effect size, 0.43), negative symptoms (-5.2 vs. -3.3; effect size, 0.33), disorganized thought (-4.9 vs. -2.8; effect size, 0.42), hostility/excitement (-2.7 vs. -1.6; effect size, 0.31), and depression/anxiety (-3.2 vs. -2.3; effect size, 0.31). Separation from placebo occurred at Week 1 for the positive symptoms, disorganized thought, and hostility/excitement factors and at Week 2 for the other factors.
CONCLUSIONS:
In this pooled analysis of short-term studies in patients with acute schizophrenia, lurasidone demonstrated significant improvement for each of the five PANSS factor scores, indicating effectiveness across the spectrum of schizophrenia symptoms.
AuthorsA Loebel, J Cucchiaro, R Silva, Y Mao, J Xu, A Pikalov, S R Marder
JournalEuropean psychiatry : the journal of the Association of European Psychiatrists (Eur Psychiatry) Vol. 30 Issue 1 Pg. 26-31 (Jan 2015) ISSN: 1778-3585 [Electronic] England
PMID25280429 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
CopyrightPublished by Elsevier Masson SAS.
Chemical References
  • Antipsychotic Agents
  • Lurasidone Hydrochloride
Topics
  • Adult
  • Antipsychotic Agents (therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Lurasidone Hydrochloride (therapeutic use)
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Randomized Controlled Trials as Topic
  • Schizophrenia (drug therapy)
  • Schizophrenic Psychology
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: